{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:32:48Z","timestamp":1793212368398,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>rFVIIa, a human recombinant activated coagulation factor VII, has been used worldwide for more than two decades for the treatment of bleeding episodes and prevention of bleeding in patients undergoing surgery\/invasive procedures with congenital haemophilia A or B with inhibitors (CHwI A or B), acquired haemophilia (AH), congenital factor VII deficiency and Glanzmann thrombasthenia (GT), refractory to platelet transfusion. The approved dosage, administration and indication of rFVIIa in the US, Europe and Japan differ, depending on the needs of the patient population and regulatory practices. This review presents an overview of the current status and future prospects, including that from a Japanese perspective, of using rFVIIa in the treatment of approved indications. The efficacy and safety of rFVIIa in the approved indications has been demonstrated in several randomised and observational studies and data from registries. The overall incidence of thrombosis across all approved indications in a retrospective safety assessment of clinical trials and registries, prelicensure studies and postmarketing surveillance studies of rFVIIa use was 0.17%. Specifically, the risk of thrombotic events was 0.11% for CHwI, 1.77% for AH, 0.82% for congenital factor VII deficiency and 0.19% for GT. Emerging non-factor therapies such as emicizumab have changed the treatment landscape of haemophilia A, including preventing bleeding in patients with CHwI. However, rFVIIa will continue to play a significant role in the treatment of such patients, particularly during breakthrough bleeding or surgical procedures.<\/jats:p>","DOI":"10.1007\/s00277-023-05287-2","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T21:01:21Z","timestamp":1688158881000},"page":"2647-2658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven\u00ae, in the treatment of haemophilia and rare bleeding disorders"],"prefix":"10.1007","volume":"103","author":[{"given":"Midori","family":"Shima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"5287_CR1","unstructured":"NovoSeven\u00aeRT (2020) Coagulation factor VIIa (Recombinant). https:\/\/www.novo-pi.com\/novosevenrt.pdf. Accessed 30 Jun 2021"},{"key":"5287_CR2","unstructured":"SevenFact. Prescribing information. https:\/\/www.fda.gov\/media\/136610\/download. Accessed 1 Sept 2022"},{"key":"5287_CR3","unstructured":"CevenFacta. Press approval release. https:\/\/www.groupe-lfb.com\/lfb-content\/uploads\/2022\/07\/pr_approval_cevenfacta_europe_mexico_final-lfb.pdf. Accessed 1 Sept 2022"},{"key":"5287_CR4","unstructured":"NovoSeven Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/novoseven-epar-product-information_en.pdf. Accessed 2 Nov 2021"},{"key":"5287_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/jth.12844","volume":"13","author":"G Lavigne-Lissalde","year":"2015","unstructured":"Lavigne-Lissalde G, Aya AG, Mercier FJ et al (2015) Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. J Thromb Haemost 13:520\u2013529","journal-title":"J Thromb Haemost"},{"key":"5287_CR6","unstructured":"NovoSeven\u00ae (2018) HI syringe interview form, version 5. https:\/\/www.info.pmda.go.jp\/go\/interview\/1\/620023_6343434D6020_1_006_1F.pdf. Accessed 3 Jul 2021"},{"key":"5287_CR7","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/hae.13845","volume":"25","author":"SL Meeks","year":"2019","unstructured":"Meeks SL, Leissinger CA (2019) The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors. Haemophilia 25:911\u2013918","journal-title":"Haemophilia"},{"key":"5287_CR8","unstructured":"Subcommittee H. 2004 activity report: Addition of indications for acquired hemophilia of Novo Seven: Japanese Society on Thrombosis and Hemostasis. https:\/\/www.jsth.org\/com\/c1\/c1-1\/. Accessed 12 Aug 2021"},{"key":"5287_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/hae.13005","volume":"22","author":"M Shima","year":"2016","unstructured":"Shima M, Lillicrap D, Kruse-Jarres R (2016) Alternative therapies for the management of inhibitors. Haemophilia 22:36\u201341","journal-title":"Haemophilia"},{"key":"5287_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2516.2006.01180.x","volume":"12","author":"G Mariani","year":"2006","unstructured":"Mariani G, Konkle BA, Ingerslev J (2006) Congenital factor VII deficiency: therapy with recombinant activated factor VII \u2013 a critical appraisal. Haemophilia 12:19\u201327","journal-title":"Haemophilia"},{"key":"5287_CR11","unstructured":"NovoSeven: U.S. Food and Drug Administration (2004) Orphan Drug Designations and Approvals. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/listResult.cfm. Accessed 1 Sept 2022"},{"key":"5287_CR12","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00277-018-3372-z","volume":"97","author":"A Tiede","year":"2018","unstructured":"Tiede A, Worster A (2018) Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia. Ann Hematol 97:1889\u20131901","journal-title":"Ann Hematol"},{"key":"5287_CR13","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1111\/hae.12852","volume":"22","author":"AD Ma","year":"2016","unstructured":"Ma AD, Kessler CM, Al-Mondhiry HA, Gut RZ, Cooper DL (2016) US experience with recombinant factor VIIa for surgery and other invasive procedures in acquired haemophilia: analysis from the Hemostasis and Thrombosis Research Society Registry. Haemophilia 22:e18\u2013e24","journal-title":"Haemophilia"},{"key":"5287_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1365-2516.2009.02198.x","volume":"16","author":"M Carcao","year":"2010","unstructured":"Carcao M, Lambert T (2010) Prophylaxis in haemophilia with inhibitors: update from international experience. Haemophilia 16:16\u201323","journal-title":"Haemophilia"},{"key":"5287_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/hae.13033","volume":"23","author":"K Amano","year":"2017","unstructured":"Amano K, Seita I, Higasa S, Sawada A, Kuwahara M, Shima M (2017) Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data. Haemophilia 23:50\u201358","journal-title":"Haemophilia"},{"key":"5287_CR16","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1111\/hae.14291","volume":"27","author":"G Dolan","year":"2021","unstructured":"Dolan G, Astermark J, Hermans C (2021) Recombinant FVIIa in elective non-orthopaedic surgery of adults with haemophilia and inhibitors: a systematic literature review. Haemophilia 27:e314\u2013e330","journal-title":"Haemophilia"},{"key":"5287_CR17","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1111\/hae.13598","volume":"24","author":"JP Jayakar","year":"2018","unstructured":"Jayakar JP, O\u2019Neill N, Yan M, Nisenbaum R, Garvey MB, Teitel J, Sholzberg M (2018) Retrospective review of acquired haemophilia A from the largest Canadian haemophilia treatment centre. Haemophilia 24:e383\u2013e387","journal-title":"Haemophilia"},{"key":"5287_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/hae.12611","volume":"21","author":"H Takedani","year":"2015","unstructured":"Takedani H, Shima M, Horikoshi Y, Koyama T, Fukutake K, Kuwahara M, Ishiguro N (2015) Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan. Haemophilia 21:374\u2013379","journal-title":"Haemophilia"},{"key":"5287_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2516.2010.02460.x","volume":"17","author":"LA Valentino","year":"2011","unstructured":"Valentino LA, Cooper DL, Goldstein B (2011) Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. Haemophilia 17:579\u2013589","journal-title":"Haemophilia"},{"key":"5287_CR20","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/hae.13482","volume":"24","author":"CM Kessler","year":"2018","unstructured":"Kessler CM, Benchikh El Fegoun S, Worster A (2018) Methodologies for data collection in congenital haemophilia with inhibitors (CHwI): critical assessment of the literature and lessons learned from recombinant factor VIIa. Haemophilia 24:536\u2013547","journal-title":"Haemophilia"},{"key":"5287_CR21","first-page":"1031","volume":"100","author":"G Di Minno","year":"2015","unstructured":"Di Minno G, Zotz RB, d\u2019Oiron R, Bindslev N, Di Minno MN, Poon MC, Glanzmann Thrombasthenia Registry Investigators (2015) The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia. Haematologica 100:1031\u20131037","journal-title":"Haematologica"},{"key":"5287_CR22","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/MBC.0000000000000471","volume":"27","author":"AD Ma","year":"2016","unstructured":"Ma AD, Kessler CM, Al-Mondhiry HA, Gut RZ, Cooper DL (2016) Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study. Blood Coagul Fibrinolysis 27:753\u2013760","journal-title":"Blood Coagul Fibrinolysis"},{"key":"5287_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1365-2141.2010.08287.x","volume":"152","author":"G Mariani","year":"2011","unstructured":"Mariani G, Dolce A, Batorova A et al (2011) Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation \u2013 the surgical STER. Br J Haematol 152:340\u2013346","journal-title":"Br J Haematol"},{"key":"5287_CR24","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3324\/haematol.2012.074039","volume":"98","author":"M Napolitano","year":"2013","unstructured":"Napolitano M, Giansily-Blaizot M, Dolce A et al (2013) Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica 98:538\u2013544","journal-title":"Haematologica"},{"key":"5287_CR25","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ajh.24741","volume":"92","author":"M Recht","year":"2017","unstructured":"Recht M, Rajpurkar M, Chitlur M, d\u2019Oiron R, Zotz R, Di Minno G, Cooper DL, Poon MC (2017) Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann\u2019s thrombasthenia registry. Am J Hematol 92:646\u2013652","journal-title":"Am J Hematol"},{"key":"5287_CR26","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/j.1365-2516.2009.02007.x","volume":"15","author":"P Salaj","year":"2009","unstructured":"Salaj P, Brabec P, Penka M, Pohlreichova V, Smejkal P, Cetkovsky P, Dusek L, Hedner U (2009) Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 15:752\u2013759","journal-title":"Haemophilia"},{"key":"5287_CR27","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1365-2516.2012.02864.x","volume":"18","author":"G Young","year":"2012","unstructured":"Young G, Cooper DL, Gut RZ (2012) Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004\u20132008). Haemophilia 18:990\u2013996","journal-title":"Haemophilia"},{"key":"5287_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1160\/TH12-07-0476","volume":"109","author":"G Mariani","year":"2013","unstructured":"Mariani G, Napolitano M, Dolce A et al (2013) Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation. Thromb Haemost 109:238\u2013247","journal-title":"Thromb Haemost"},{"key":"5287_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2147\/JBM.S219573","volume":"10","author":"M Rajpurkar","year":"2019","unstructured":"Rajpurkar M, Croteau SE, Boggio L, Cooper DL (2019) Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC). J Blood Med 10:335\u2013340","journal-title":"J Blood Med"},{"key":"5287_CR30","first-page":"275","volume":"5","author":"L Butros","year":"2011","unstructured":"Butros L, Boayue K, Mathew P (2011) Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa. Drug Des Develop Ther 5:275\u2013282","journal-title":"Drug Des Develop Ther"},{"key":"5287_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3324\/haematol.2019.239160","volume":"106","author":"C Male","year":"2021","unstructured":"Male C, Andersson NG, Rafowicz A et al (2021) Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica 106:123\u2013129","journal-title":"Haematologica"},{"key":"5287_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A et al (2020) WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 26:1\u2013158","journal-title":"Haemophilia"},{"key":"5287_CR33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/1076029614555902","volume":"22","author":"M Faranoush","year":"2016","unstructured":"Faranoush M, Abolghasemi H, Mahboudi F et al (2016) A comparison of efficacy between recombinant activated factor VII (Aryoseven) and novoseven in patients with hereditary FVIII deficiency with inhibitor. Clin Appl Thromb Hemost 22:184\u2013190","journal-title":"Clin Appl Thromb Hemost"},{"key":"5287_CR34","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1160\/TH05-07-0510","volume":"95","author":"K Kavakli","year":"2006","unstructured":"Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G, NovoSeven trial (F7HAEM-1510) investigators (2006) Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 95:600\u2013605","journal-title":"Thromb Haemost"},{"key":"5287_CR35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","volume":"109","author":"J Astermark","year":"2007","unstructured":"Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E, FENOC Study Group (2007) A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 109:546\u2013551","journal-title":"Blood"},{"key":"5287_CR36","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1538-7836.2006.01772.x","volume":"4","author":"E Santagostino","year":"2006","unstructured":"Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM (2006) A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 4:367\u2013371","journal-title":"J Thromb Haemost"},{"key":"5287_CR37","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/jth.12634","volume":"12","author":"SR Lentz","year":"2014","unstructured":"Lentz SR, Ehrenforth S, Karim FA, Matsushita T, Weldingh KN, Windyga J, Mahlangu JN, adept\u21222 investigators (2014) Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost 12:1244\u20131253","journal-title":"J Thromb Haemost"},{"key":"5287_CR38","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/hae.12140","volume":"19","author":"H Chambost","year":"2013","unstructured":"Chambost H, Santagostino E, Laffan M, Kavakli K, ONE Registry Steering Committee on behalf of the investigators (2013) Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry. Haemophilia 19:571\u2013577","journal-title":"Haemophilia"},{"key":"5287_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1600-0609.1998.tb01103.x","volume":"63","author":"JM Lusher","year":"1998","unstructured":"Lusher JM (1998) Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 63:7\u201310","journal-title":"Eur J Haematol Suppl"},{"key":"5287_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2516.2006.01359.x","volume":"12","author":"E Berntorp","year":"2006","unstructured":"Berntorp E, Shapiro A, Astermark J et al (2006) Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 12:1\u20137","journal-title":"Haemophilia"},{"key":"5287_CR41","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ajh.24811","volume":"92","author":"G Young","year":"2017","unstructured":"Young G, Escobar MA, Pipe SW, Cooper DL (2017) Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: a review of clinical studies and registries. Am J Hematol 92:940\u2013945","journal-title":"Am J Hematol"},{"key":"5287_CR42","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/hae.13357","volume":"23","author":"J Ducore","year":"2017","unstructured":"Ducore J, Lawrence JB, Simpson M et al (2017) Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors. Haemophilia 23:844\u2013851","journal-title":"Haemophilia"},{"key":"5287_CR43","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/hae.13301","volume":"23","author":"M Wang","year":"2017","unstructured":"Wang M, Lawrence JB, Quon DV et al (2017) PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding. Haemophilia 23:832\u2013843","journal-title":"Haemophilia"},{"key":"5287_CR44","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/hae.14563","volume":"28","author":"SW Pipe","year":"2022","unstructured":"Pipe SW, Hermans C, Chitlur M et al (2022) Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia 28:548\u2013556","journal-title":"Haemophilia"},{"key":"5287_CR45","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/hae.14418","volume":"27","author":"M Escobar","year":"2021","unstructured":"Escobar M, Luck J, Averianov Y et al (2021) PERSEPT 3: a phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia 27:911\u2013920","journal-title":"Haemophilia"},{"key":"5287_CR46","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/hae.14419","volume":"27","author":"M Escobar","year":"2021","unstructured":"Escobar M, Castaman G, Boix SB et al (2021) The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia 27:921\u2013931","journal-title":"Haemophilia"},{"key":"5287_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/17474086.2019.1560259","volume":"12","author":"C Biron-Andreani","year":"2019","unstructured":"Biron-Andreani C, Schved JF (2019) Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors. Expert Rev Hematol 12:21\u201328","journal-title":"Expert Rev Hematol"},{"key":"5287_CR48","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1177\/10600280211049394","volume":"56","author":"AM Ciolek","year":"2022","unstructured":"Ciolek AM, Arnall J, Moore DC, Palkimas S, Der-Nigoghossian J, Dane K (2022) Eptacog beta for bleeding treatment and prevention in congenital hemophilia A and B with inhibitors: a review of clinical data and implications for clinical practice. Ann Pharmacother 56:831\u2013838","journal-title":"Ann Pharmacother"},{"key":"5287_CR49","volume-title":"Acquired hemophilia","author":"MZ Haider","year":"2021","unstructured":"Haider MZ, Anwer F (2021) Acquired hemophilia. StatPearls Publishing, Treasure Island (FL)"},{"key":"5287_CR50","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","volume":"105","author":"A Tiede","year":"2020","unstructured":"Tiede A, Collins P, Knoebl P et al (2020) International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica 105:1791\u20131801","journal-title":"Haematologica"},{"key":"5287_CR51","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","volume":"120","author":"F Baudo","year":"2012","unstructured":"Baudo F, Collins P, Huth-K\u00fchne A et al (2012) Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 120:39\u201346","journal-title":"Blood"},{"key":"5287_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/JBM.S55216","volume":"5","author":"SR Lentz","year":"2014","unstructured":"Lentz SR, Tandra A, Gut RZ, Cooper DL (2014) A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project. J Blood Med 5:1\u20133","journal-title":"J Blood Med"},{"key":"5287_CR53","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1365-2516.2008.01829.x","volume":"14","author":"T Abshire","year":"2008","unstructured":"Abshire T, Kenet G (2008) Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 14:898\u2013902","journal-title":"Haemophilia"},{"key":"5287_CR54","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1365-2141.2011.08854.x","volume":"155","author":"J Ingerslev","year":"2011","unstructured":"Ingerslev J, S\u00f8rensen B (2011) Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol 155:256\u2013262","journal-title":"Br J Haematol"},{"key":"5287_CR55","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/bloodadvances.2017008409","volume":"1","author":"CD Seaman","year":"2017","unstructured":"Seaman CD, Ragni MV (2017) Sequential bypassing agents during major orthopedic surgery: a new approach to hemostasis. Blood Adv 1:1309\u20131311","journal-title":"Blood Adv"},{"key":"5287_CR56","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1182\/bloodadvances.2019000228","volume":"3","author":"CD Seaman","year":"2019","unstructured":"Seaman CD, Ragni MV (2019) Emicizumab use in major orthopedic surgery. Blood Adv 3:1722\u20131724","journal-title":"Blood Adv"},{"key":"5287_CR57","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1046\/j.1365-2516.2002.00626.x","volume":"8","author":"D Dimichele","year":"2002","unstructured":"Dimichele D (2002) Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 8:280\u2013287","journal-title":"Haemophilia"},{"issue":"4","key":"5287_CR58","doi-asserted-by":"publisher","first-page":"282","DOI":"10.5045\/br.2013.48.4.282","volume":"48","author":"MH Han","year":"2013","unstructured":"Han MH, Park YS (2013) Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience. Blood Res 48(4):282\u2013286","journal-title":"Blood Res"},{"key":"5287_CR59","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/j.1365-2516.2010.02467.x","volume":"17","author":"A Gringeri","year":"2011","unstructured":"Gringeri A, Fischer K, Karafoulidou A, Klamroth R, L\u00f3pez-Fern\u00e1ndez MF, Mancuso E (2011) European Haemophilia Treatment Standardisation Board (EHTSB). Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia 17:630\u2013635","journal-title":"Haemophilia"},{"key":"5287_CR60","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1365-2516.2007.01451.x","volume":"13","author":"J Schneiderman","year":"2007","unstructured":"Schneiderman J, Rubin E, Nugent DJ, Young G (2007) Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 13:244\u2013248","journal-title":"Haemophilia"},{"key":"5287_CR61","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1182\/blood-2014-08-532820","volume":"125","author":"R Palla","year":"2015","unstructured":"Palla R, Peyvandi F, Shapiro AD (2015) Rare bleeding disorders: diagnosis and treatment. Blood 125:2052\u20132061","journal-title":"Blood"},{"key":"5287_CR62","first-page":"289","volume":"11","author":"A Duncan","year":"2020","unstructured":"Duncan A, Kellum A, Peltier S, Cooper DL, Saad H (2020) Disease burden in patients with Glanzmann\u2019s thrombasthenia: perspectives from the Glanzmann\u2019s thrombasthenia patient\/caregiver questionnaire. J Blood Med 11:289\u2013295","journal-title":"J Blood Med"},{"key":"5287_CR63","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1750-1172-1-10","volume":"1","author":"AT Nurden","year":"2006","unstructured":"Nurden AT (2006) Glanzmann thrombasthenia. Orphanet J Rare Dis 1:10","journal-title":"Orphanet J Rare Dis"},{"key":"5287_CR64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2147\/JBM.S71319","volume":"6","author":"T Solh","year":"2015","unstructured":"Solh T, Botsford A, Solh M (2015) Glanzmann\u2019s thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. J Blood Med 6:219\u2013227","journal-title":"J Blood Med"},{"key":"5287_CR65","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/bjh.15087","volume":"181","author":"M Fiore","year":"2018","unstructured":"Fiore M, d\u2019Oiron R, Pillois X, Alessi MC (2018) Anti-\u03b1(IIb) \u03b2(3) immunization in Glanzmann thrombasthenia: review of literature and treatment recommendations. Br J Haematol 181:173\u2013182","journal-title":"Br J Haematol"},{"key":"5287_CR66","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/IJGM.S128953","volume":"10","author":"M Chitlur","year":"2017","unstructured":"Chitlur M, Rajpurkar M, Recht M, Tarantino MD, Yee DL, Cooper DL, Gunawardena S (2017) Recognition and management of platelet-refractory bleeding in patients with Glanzmann\u2019s thrombasthenia and other severe platelet function disorders. Int J Gen Med 10:95\u201399","journal-title":"Int J Gen Med"},{"key":"5287_CR67","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1055\/s-0040-1718373","volume":"121","author":"MC Poon","year":"2021","unstructured":"Poon MC (2021) The use of recombinant activated factor VII in patients with Glanzmann\u2019s thrombasthenia. Thromb Haemost 121:332\u2013340","journal-title":"Thromb Haemost"},{"key":"5287_CR68","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12185-018-2545-9","volume":"111","author":"T Kitazawa","year":"2020","unstructured":"Kitazawa T, Shima M (2020) Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity. Int J Hematol 111:20\u201330","journal-title":"Int J Hematol"},{"key":"5287_CR69","unstructured":"European Medicines Agency. Hemlibra summary of risk management plan for Hemlibra (emicizumab). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hemlibra. [updated 12 April 2019]. https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/hemlibra-epar-risk-management-plan-summary_en.pdf. Accessed 31 Jan 2022"},{"key":"5287_CR70","unstructured":"Emicizumab prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761083s000lbl.pdf. Accessed 1 Sept 2022"},{"key":"5287_CR71","doi-asserted-by":"publisher","first-page":"e12508","DOI":"10.1002\/rth2.12508","volume":"5","author":"C Hermans","year":"2021","unstructured":"Hermans C, Makris M (2021) Disruptive technology and hemophilia care: the multiple impacts of emicizumab. Res Pract Thromb Haemost 5:e12508","journal-title":"Res Pract Thromb Haemost"},{"key":"5287_CR72","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1182\/blood.2020009217","volume":"137","author":"MU Callaghan","year":"2021","unstructured":"Callaghan MU, Negrier C, Paz-Priel I et al (2021) Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1\u20134 studies. Blood 137:2231\u20132242","journal-title":"Blood"},{"key":"5287_CR73","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.3390\/jcm10194303","volume":"10","author":"S Levy-Mendelovich","year":"2021","unstructured":"Levy-Mendelovich S, Brutman-Barazani T, Budnik I et al (2021) Real-world data on bleeding patterns of hemophilia a patients treated with emicizumab. J Clin Med 10:4303","journal-title":"J Clin Med"},{"key":"5287_CR74","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/hae.13817","volume":"25","author":"S Susen","year":"2019","unstructured":"Susen S, Gruel Y, Godier A et al (2019) Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra(\u00ae)): proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP). Haemophilia 25:731\u2013737","journal-title":"Haemophilia"},{"key":"5287_CR75","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/hae.14322","volume":"27","author":"V Jim\u00e9nez-Yuste","year":"2021","unstructured":"Jim\u00e9nez-Yuste V, Rodr\u00edguez-Merch\u00e1n EC, Matsushita T, Holme PA (2021) Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery. Haemophilia 27:519\u2013530","journal-title":"Haemophilia"},{"key":"5287_CR76","unstructured":"SEVENFACT\u00ae for bleeding events in hemophilia with inhibitors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04647227?term=sevenfact&draw=2&rank=1. Accessed 1 Sept 2022"},{"key":"5287_CR77","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1182\/bloodadvances.2019001140","volume":"5","author":"AD Shapiro","year":"2021","unstructured":"Shapiro AD (2021) Concizumab: a novel anti-TFPI therapeutic for hemophilia. Blood Adv 5:279","journal-title":"Blood Adv"},{"issue":"Supplement_1","key":"5287_CR78","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1182\/blood-2019-122301","volume":"134","author":"M Kjalke","year":"2019","unstructured":"Kjalke M, Kjelgaard-Hansen M, Andersen S, Hilden I (2019) Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC. Blood 134(Supplement_1):3639","journal-title":"Blood"},{"key":"5287_CR79","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/jth.14380","volume":"17","author":"B Lauritzen","year":"2019","unstructured":"Lauritzen B, Olling J, Abel KL, Augustsson C, Balling K, Bjelke M, Hegelund AC, Hilden I (2019) Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits. J Thromb Haemost 17:460\u2013469","journal-title":"J Thromb Haemost"},{"key":"5287_CR80","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1182\/blood.2019001542","volume":"134","author":"AD Shapiro","year":"2019","unstructured":"Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P et al (2019) Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results. Blood 134:1973\u20131982","journal-title":"Blood"},{"key":"5287_CR81","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1182\/bloodadvances.2021006403","volume":"6","author":"AD Shapiro","year":"2022","unstructured":"Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Eichler H et al (2022) Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors. Blood Adv 6:3422\u20133432","journal-title":"Blood Adv"},{"key":"5287_CR82","unstructured":"Compassionate Use of Concizumab if You Have Haemophilia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04921956. Accessed 10 May 2023"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05287-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05287-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05287-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:03:59Z","timestamp":1722060239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05287-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":82,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5287"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05287-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"assertion":[{"value":"27 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Midori Shima reports participation on advisory board for Chugai, Fujimoto Seiyaku, speaker fee and honorarium from Chugai, Roche, CSL-Behring, Fujimoto Seiyaku, Sanofi, Pfizer, Takeda, Novo Nordisk, Bayer and research funding from CSL-Behring and Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}